Evidence map›Paper›PMID 40584572›Full record

ArticleMolecular therapy. Methods & clinical development2025

Dose-finding and

Wei Huang, Tawfiq Mohammed, Xunchang Zou, Anya A Krishnan, Xiaokui Mo, Min Xiao, Lei Cao

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei HuangDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Tawfiq MohammedDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Xunchang ZouDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Anya A KrishnanDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Xiaokui MoDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Min XiaoDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Lei CaoDepartment of Cancer Biology & Genetics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.

Funding

Novel Adipose Targeted Gene Therapy for LipodystrophyR41DK138551 · NIDDK · ZVELT THERAPEUTICS INC. · PI CAO, LEI, HAWKINS, AL · 2023 to 2023
$294k
NIDDK NIH HHS R41 DK138551
6 · The paper itself

Abstract

Congenital leptin deficiency is a monogenic disease originated from adipose tissue, causing hyperphagia, severe obesity, and hyperinsulinemia. Moreover, most forms of lipodystrophy syndromes exhibit leptin deficiency. Leptin replacement therapy with leptin protein analog requires frequent injection for life and is extremely expensive. We previously reported that a single intraperitoneal injection of an adipose-targeting Rec2-leptin adeno-associated virus (AAV) vector normalized metabolic syndromes in the leptin deficient

Indexed as

AAVadipose-targetinggene therapyintraperitoneal administrationleptinleptin deficiencylipodystrophymetabolic syndromeobesityvisceral fat

Identifiers

PMID40584572
PMCPMC12205552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.